Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Stock Information for Compass Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Compass Therapeutics Inc.

Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Compass Therapeutics to Participate in Upcoming Investor Events
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.